The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults

Vaccine

Volumn 21, Issue 3-4, 2002, Pages 322-329

  Evans, Thomas G ^a   Hasan, Muhammad ^b   Galibert, Laurent ^c   Caron, Dania ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c AMGEN INC   (United States)

Author keywords

Cytokines; Vaccination; Viral

Indexed keywords

ANTIBODY; CD123 ANTIGEN; FLT3 LIGAND; GLYCOPROTEIN P 15095; HEPATITIS B VACCINE; HLA DR ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; FLT3 LIGAND PROTEIN; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN;

ADJUVANT THERAPY; ADULT; ANTIBODY TITER; ARTICLE; CELL LINEAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ECCHYMOSIS; HEPATITIS B; HUMAN; LEUKOCYTE COUNT; METHODOLOGY; MONOCYTE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STEM CELL; VACCINATION; VOLUNTEER; BLOOD; CYTOLOGY; FEMALE; IMMUNOLOGY; MALE; SAFETY;

ADJUVANTS, IMMUNOLOGIC; ADULT; DENDRITIC CELLS; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MALE; MEMBRANE PROTEINS; SAFETY; VACCINATION;

EID: 0037073603     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00454-1     Document Type: Article

References (37)

1. Gupta R.K., Siber G.R. Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. Biologicals. 22(1):1994;53-63.
2. Lin R., Tarr P.E., Jones T.C. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin. Infect. Dis. 21(6):1995;1439-1449.
3. Gupta R.K., Siber G.R. Adjuvants for human vaccines - current status. Vaccine. 13(14):1995;1263-1276.
4. Banchereau J. Dendritic cells: therapeutic potentials. Transfus. Sci. 18(2):1997;313-326.
5. Lynch D.H. Induction of dendritic cells (DC) by Flt3 ligand (FL) promotes the generation of tumor-specific immune responses in vivo. Crit. Rev. Immunol. 18(1-2):1998;99-107.
6. Lyman S.D. Biologic effects and potential clinical applications of Flt3 ligand. Curr. Opin. Hematol. 5(3):1998;192-196.
7. Maraskovsky E., Daro E., Roux E.et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood. 96(3):2000;878-884.
8. Maraskovsky E., Brasel K., Teepe M.et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184(5):1996;1953-1962.
9. Maraskovsky E., Pulendran B., Brasel K.et al. Dramatic numerical increase of functionally mature dendritic cells in Flt3 ligand-treated mice. Adv. Exp. Med. Biol. 417:1997;33-40.
10. Lyman S.D., Jacobsen S.E. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood. 91(4):1998;1101-1134.
11. Pulendran B., Lingappa J., Kennedy M.K.et al. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in Flt3 ligand-treated mice. J. Immunol. 159(5):1997;2222-2231.
12. Pulendran B., Smith J.L., Jenkins M., Schoenborn M., Maraskovsky E., Maliszewski C.R. Prevention of peripheral tolerance by a dendritic cell growth factor: Flt3 ligand as an adjuvant. J. Exp. Med. 188(11):1998;2075-2082.
13. McKenna H.J., Stocking K.L., Miller R.E.et al. Mice lacking Flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, and natural killer cells, dendritic cells. Blood. 95(11):2000;3489-3497.
14. Pulendran B., Banchereau J., Burkeholder S.et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165(1):2000;566-572.
15. Chang M.H., Chen C.J., Lai M.S.et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. New Engl. J. Med. 336(26):1997;1855-1859. [see comments].
16. Hasan M.S., Agosti J.M., Reynolds K.K., Tanzman E., Treanor J.J., Evans T.G. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. J. Infect. Dis. 180(6):1999;2023-2026.
17. Alimonos K., Nafziger A.N., Murray J., Bertino J.S. Jr. Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness? Clin. Infect. Dis. 26(3):1998;566-571. [see comments].
18. West D.J. Clinical experience with hepatitis B vaccines. Am. J. Infect. Control. 17(3):1989;172-180.
19. Lyman S.D., James L., Vanden Bos T.et al. Molecular cloning of a ligand for the Flt3/Flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell. 75(6):1993;1157-1167.
20. Banchereau J., Briere F., Caux C.et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:2000;767-811.
21. Rissoan M.C., Soumelis V., Kadowaki N.et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 283(5405):1999;1183-1186. [see comments].
22. Shurin M.R., Pandharipande P.P., Zorina T.D.et al. Flt3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol. 179(2):1997;174-184.
23. + subset of human blood dendritic cells is a direct precursor of Langerhans cells. J. Immunol. 163(3):1999;1409-1419.
24. Drakes M.L., Lu L., Subbotin V.M., Thomson A.W. In vivo administration of Flt3 ligand markedly stimulates generation of dendritic cell progenitors from mouse liver. J. Immunol. 159(9):1997;4268-4278.
25. Strobl H., Bello-Fernandez C., Riedl E. Flt3 ligand in cooperation with transforming growth factor-beta1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood. 90(4):1997;1425-1434.
26. + peripheral blood dendritic cells are differentially regulated by cytokines. J. Immunol. 163(6):1999;3250-3259.
27. Grouard G., Rissoan M.C., Filgueira L., Durand I., Banchereau J., Liu Y.J. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med. 185(6):1997;1101-1111.
28. Brasel K., McKenna H.J., Morrissey P.J.et al. Hematologic effects of Flt3 ligand in vivo in mice. Blood. 88(6):1996;2004-2012.
29. Yu H., Fehniger T.A., Fuchshuber P.et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood. 92(10):1998;3647-3657.
30. - population. Blood. 93(7):1999;2302-2307.
31. high) dendritic cells in human nasal allergy. J. Immunol. 165(7):2000;4062-4068. [in process citation].
32. Chen K., Braun S., Lyman S.et al. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 57(16):1997;3511-3516.
33. Mach N., Gillessen S., Wilson S.B., Sheehan C., Mihm M., Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 60(12):2000;3239-3246.
34. Daro E., Pulendran B., Brasel K.et al. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but not CD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J. Immunol. 165(1):2000;49-58.
35. Drake D.R. Jr., Moser J.M., Hadley A.et al. Polyomavirus-infected dendritic cells induce antiviral CD8(+) T lymphocytes. J. Virol. 74(9):2000;4093-4101.
36. Borges L., Miller R.E., Jones J.et al. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J. Immunol. 163(3):1999;1289-1297.
37. + T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J. Clin. Immunol. 21(1):2001;30-36.